# Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)

Study · id `cardio:ct-nct03234114` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03234114](<https://clinicaltrials.gov/study/NCT03234114>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03234114

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 3746 participants.

## Technical summary

Registry record NCT03234114. Randomized; no masking; primary purpose treatment. Start 2018-02-03 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3746 participants (planned count; ClinicalTrials.gov record NCT03234114, source copy `cardio:ctgov-nct03234114-2023-04-24`, retrieved 2026-10-31)
- Started: 2018-02-03 (actual) (ClinicalTrials.gov record NCT03234114, source copy `cardio:ctgov-nct03234114-2023-04-24`, retrieved 2026-10-31)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT03234114, source copy `cardio:ctgov-nct03234114-2023-04-24`, retrieved 2026-10-31)
- Completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT03234114, source copy `cardio:ctgov-nct03234114-2023-04-24`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT03234114, source copy `cardio:ctgov-nct03234114-2023-04-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03234114-2023-04-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)
- Condition: Acute Coronary Syndrome (ACS)
- Condition: Non-valvular Atrial Fibrillation (NVAF)
- Intervention (Drug): Triple antithrombotic therapy
- Intervention (Drug): Dual antithrombotc therapy-1
- Intervention (Drug): Dual antithrombotc therapy-2
- Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital with Nanjing Medical University (`cardio:org-the-first-affiliated-hospital-with-nanjing-medical-898271`)

## Provenance

Content hash: dca39f095029e7752c52323cf76d18ba909806bc607681c9f6246e8330c50154
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
